ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: PUB278

Effect of Hypertension on Incident ESKD Across Various Diabetes Stages: A Nationwide Population-Based Cohort Study

Session Information

Category: Hypertension and CVD

  • 1601 Hypertension and CVD: Basic

Authors

  • Park, Hyeran, St. Vincent’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea (the Republic of)
  • Kim, Yong Kyun, St. Vincent’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea (the Republic of)
  • Kim, Hyunglae, St. Vincent’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea (the Republic of)
  • Kim, Hyung Wook, St. Vincent’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea (the Republic of)
Background

Diabetes and hypertension are recognized risk factors for the progression to end-stage kidney disease (ESKD). However, limited studies have investigated the interaction between these two conditions, particularly how pre-diabetes and pre-hypertension influence ESKD incidence. This study aims to assess the hazard ratios (HRs) for ESKD development based on diabetes and hypertension status, including pre-disease states, with further analyses stratified by sex and age.

Methods

This retrospective cohort study involved 4,595,974 adults aged ≥20 years who participated in national health screenings in 2012, with follow-up until 2019. Participants were divided into five diabetes groups (normal, impaired fasting glucose (IFG), newly diagnosed, <5 years, and ≥5 years duration) and five hypertension groups (normal, prehypertension, newly diagnosed, controlled, and uncontrolled hypertension). HRs for ESKD development were calculated for each group, with additional analyses based on sex, age, chronic kidney disease, and proteinuria status.

Results

The risk of ESKD increased progressively with worsening stages of hypertension in all diabetes groups, with the highest risk observed in those with diabetes for more than 5 years and uncontrolled hypertension (HR, 73.581; 95% CI [65.346, 82.855]) when compared to the normoglycemic and normotensive groups. Hypertension had a smaller impact on ESKD risk in the IFG group compared to both the diabetes and normoglycemic groups. Subgroup analyses revealed that hypertension posed a greater risk for ESKD in patients younger than 65 years, regardless of diabetes status. The presence of chronic kidney disease further amplified the ESKD risk associated with hypertension, though no significant differences were found based on sex or proteinuria status.

Conclusion

ESKD risk increases with longer diabetes duration and uncontrolled hypertension, though this effect is less pronounced in individuals with IFG. In patients under 65, hypertension notably elevates ESKD risk, independent of diabetes status, emphasizing the importance of stringent blood pressure control, even in non-diabetic individuals.

Digital Object Identifier (DOI)